BACKGROUND: Graves' disease is routinely treated with antithyroid drugs (ATD), radioactive-iodine (RAI), or surgery but it is uncertain whether the choice of initial therapy influences long-term outcomes. We evaluated cardiovascular morbidity and mortality according to the modality and effectiveness of primary therapy in Graves' disease.
INTERPRETATION: Regardless of therapy modality, early and effective control of
Graves' hyperthyroidism is associated with improved survival compared to less effective control.
FUNDING: National Institute for Social Care and Health Research (NISCHR), Wales
RESEARCH IN CONTEXT

Evidence before this study
We searched PubMed for articles published up to October 2018, without language restrictions, that addressed mortality outcomes in relation to treatment modality in patients with hyperthyroidism. Our search terms were ("hyperthyroidism" OR "thyrotoxicosis" OR "Graves' disease") AND ("mortality" OR "survival") AND ("treatment" OR "antithyroid drugs" OR "thionamides" OR "radioactive iodine" OR "thyroidectomy"). Although several studies reported excess mortality in radioiodinetreated cohorts, these studies did not include patients treated with antithyroid drugs which currently represents the predominant therapy modality for Graves' disease worldwide. Only one study to date has compared hyperthyroidism mortality according to treatment with antithyroid drugs or radioiodine. This study showed survival advantages following radioiodine-induced hypothyroidism compared to during antithyroid drug treatment. However, the study comprised a heterogeneous hyperthyroid cohort that was underpowered to show treatment effects in the Graves' disease subset of 345 patients.
Added value of this study
To the best of our knowledge ours is the first study to show that early and complete resolution of hyperthyroidism in patients with Graves' disease is associated with improved survival compared to less effective control. We show that survival in patients with Graves' disease is associated with the rapid restoration of normal thyroid status rather than therapy modality per se. Using flexible spline regression modelling we demonstrate a positive association between FT4 levels after initial therapy and subsequent cardiovascular morbidity and mortality.
Implications of all the available evidence
Our findings emphasise the importance of prompt elimination of hyperthyroidism and maintenance of normal thyroid status in the care of Graves' disease patients. The choice of therapy should be driven by the prospects of successful resolution of hyperthyroidism and therefore, early definitive therapy should be offered to patients unlikely to achieve remission with antithyroid drugs alone.
INTRODUCTION
Graves' disease is the most common cause of hyperthyroidism in iodine-sufficient countries, affecting 0·5-1.0% of the population 1, 2 . Hyperthyroidism in Graves' disease results from unregulated stimulation of the thyrotropin (TSH) receptor by autoreactive TSH-receptor antibodies (TRAbs) which are detectable in virtually every patient with the disease 3 . Patients with uncorrected hyperthyroidism have an increased mortality risk and suffer significant cardiovascular morbidity including cardiac arrhythmias, strokes and heart failure 4, 5 . Three treatment modalities for Graves' disease, namely thionamide drugs, radioactive iodine, and thyroidectomy have been available for decades, all with established safety and efficacy records.
However, the approach to therapy is highly variable and largely dictated by regional preferences 2, 6 . Primary thionamide therapy is favoured by the European Thyroid Association 7 , while the American Thyroid Association endorses any of the modalities depending on individual patient characteristics 8 . In practice radioiodine is traditionally preferred in North America 9 although antithyroid drugs are increasingly used and are now the most common treatment for Graves' disease in the United States 10 . In contrast primary radioiodine therapy is less popular in Europe and Asia and remains restricted to patients who relapse following 12-18 months of thionamides 112 .
These variations in treatment are in part driven by lack of evidence regarding mortality risk with respect to Graves' disease management. Randomised controlled trials on mortality outcomes in Graves' disease are lacking and are unlikely to be undertaken given the logistic implications. Although observational studies have addressed mortality end-points in patients with hyperthyroidism 4, [12] [13] [14] [15] [16] [17] [18] , only a few studies specifically distinguished Graves' disease from other causes of hyperthyroidism 17, [19] [20] [21] [22] [23] . This distinction is relevant given that Graves' disease patients are younger and express a different cardiovascular phenotype from those with thyroid nodules 2, 5, 20, 22 . In addition, unlike patients with toxic nodules who require definitive treatment for cure, Graves' disease patients have a choice of all three treatments, underpinning the need for treatment-specific outcome data.
Although previous cohort studies have reported excess mortality in radioiodinetreated patients 15, 17, 18, 23, 24 , these cohorts excluded patients treated with thionamides which currently represents the predominant therapy modality for Graves' disease worldwide 2 . Only one study to date has compared mortality according to thionamide versus radioiodine treatment 19 . The study by Boelaert et al observed reduced mortality after radioiodine induced hypothyroidism compared to during thionamide therapy. However, the study comprised a heterogeneous hyperthyroidism clinic cohort (n=1036) that was underpowered to show treatment effects in the Graves' disease subset (n=345) 19 . Thus, it remains unclear whether primary radioiodine therapy offers survival advantages over thionamides and hence whether current Graves' disease treatment strategies are optimal. Our objective in the present study was to evaluate cardiovascular morbidity and mortality according to the modality and effectiveness of primary therapy in a large cohort of patients with Graves' disease.
METHODS
Data Sources and study population
The study was conducted through linked datasets within the Secure Anonymised Information Linkage (SAIL) Databank. SAIL is a nationwide repository of routinely collected health and social care data in Wales run by the Health Informatics Research Unit of Swansea University. The databank contains over two billion anonymised person-based records linked to hospital admission and primary care data 25 . All National Health Service (NHS) users in Wales are identified by a unique 10-digit identifier and anonymity of data within the databank is ensured by multi-party encryption through a split-file data management system 26 . For this study, we created a dataset of patients with hyperthyroidism, diagnosed between January 1998 and December 2013 in clinics across three health boards serving an estimated 1·4 million residents in South Wales. We included all patients who could be linked to the Welsh Demographic Service, a population register of individuals registered with a general practitioner (GP) or receiving healthcare in Wales. Additional outcomes were obtained from primary care data held within SAIL, covering about 75% of the population, and the Patient Episode Database for Wales (PEDW), a dataset of all inpatient admissions in Wales.
Patients with Graves' disease were identified from electronic records of TRAb tests performed at the biochemistry department of the University Hospital of Wales, Cardiff, which served as the regional TRAb-assay laboratory during the period covered by the study. TRAbs are sensitive and specific markers of Graves' disease 27 and are routinely included in the diagnostic work-up of Graves' disease in our catchment clinics. Patients were defined as Graves' Hyperthyroidism if they had a positive TRAb test together with evidence of hyperthyroidism from either: (a) low-TSH in laboratory records, (b) record of hyperthyroidism in GP or hospital datasets (ICD-10 E05, read codes C02), or (c) record of thionamide prescription in GP data (carbimazole, read codes fa1 and propylthiouracil, fa2). The patient inclusion flow chart is presented in figure 1 . For a background control population, we identified a sample of individuals in the Welsh Demographic Service, matched to cases on birth week and sex, at a ratio of 4 control subjects per patient (n=16,756). Individuals with hyperthyroidism on our loaded datasets were excluded from the controls.
Treatment and outcome data
Iodine-131 treatment data was extracted from radioiodine treatment logs in nuclear medicine departments serving the study population. Each department holds statutory records of all radioisotope treatment including isotope type, dose, and date of administration. Information on thyroidectomy was obtained from PEDW using the
Office of Population censuses and Surveys version 4 (OPCS-4) classification code
for thyroidectomy, B081-B091. Outcome events were recorded from PEDW using the relevant ICD-10 codes for atrial fibrillation (I48), acute myocardial infarction (I21-I23), acute coronary syndrome (I20), heart failure (I50), ischaemic stroke (I63, I65-I68), haemorrhagic stroke (I60-I62), diabetes mellitus (E10-E14), thyroid cancer (C73), and breast cancer (C50). Mortality information was obtained from the Office for National Statistics (ONS).
Laboratory assays
TRAbs were performed with second generation radioimmunoassays while thyroid hormones (FT4 and TSH) were performed using several different immunoassays.
The laboratory assays, reference ranges and performance measures are detailed in the supplementary appendix and supplementary table 1.
Statistical analysis
Baseline data is summarised as means (standard deviation, SD) for normally distributed values or median (interquartile range, IQR) for non-normal data.
Differences between groups were analysed with chi-squared test, 2-tailed t-test or
Mann-Whitney tests as appropriate. The primary study outcome was all-cause mortality while secondary outcome was major adverse cardiovascular events (MACE), a composite of acute myocardial infarction, ischaemic stroke, heart failure, or death. Patients were grouped according to primary treatment using a landmark approach to avoid immortal time bias. The landmark was set at one-year postdiagnosis which was considered sufficient time for primary therapy without incurring excessive data losses from pre-landmark censoring. Treatment groups comprised: (1) ATD, patients who received only antithyroid drugs in the first year of diagnosis, (2) RAI-Grp-A, patients who received radioiodine and achieved hyperthyroidism control by one-year, and (3) RAI-Grp-B, patients who received radioiodine but had not achieved hyperthyroidism control by one-year. We excluded patients if they were censored before one-year (n=93) or had thyroidectomy in the first-year due to small numbers (78 patients, 2 deaths). Control of hyperthyroidism after radioiodine was defined as levothyroxine initiation, or TSH above the reference limit, or persistent euthyroidism (>6 months), each without antithyroid drug use. The diagnosis date was the date of the first positive TRAb or low-TSH, whichever was recorded earlier, and follow-up was from diagnosis until event or study end.
We analysed outcomes according to primary treatment using Kaplan-Meier curves and Cox regression models. First, we compared event rates in patients and population controls using the logrank test and an adjusted Cox regression model to account for baseline comorbidity. The analysis was undertaken in the whole cohort and stratified by primary treatment group, with the corresponding matched population for each group as controls. In a second approach, we used a Cox regression model to compare event risk between treatment groups with the antithyroid drug group as reference category. Models were adjusted for 5-year age bands, gender, diagnosis-year, baseline TRAb concentration, and comorbidity scores, using a modification of the Charlson Comorbidity Index (supplementary table   2 ). Stratified analysis was undertaken by age (>50 vs. <50 years) and co-morbidity score (0 vs >1) with interaction terms for sub-groups. In sensitivity analysis, we sequentially excluded pregnant patients (n=63) and patients with borderline TRAb levels (n=266) at diagnosis. The validity of the proportional hazard assumption was examined by Schoenfeld residuals test and visual inspection of residuals plots against time.
As an alternative means of handling time bias, treatment and thyroid status were To directly evaluate the impact of thyroid status, we analysed outcomes according to thyroid function after one-year of treatment. We derived a one-year FT4 and TSH from time-weighted averages of all available tests at 9-12 months excluding patients censored before one-year. TSH was entered in a Cox regression model as low, normal, or high-TSH with the normal-TSH as reference category. Models were adjusted for age, gender, comorbidity, baseline TRAb, FT4 and TSH, and then stratified by primary treatment modality based on treatment received by the test date.
For FT4, we used restricted cubic splines to model a possible non-linear relationship between one-year FT4 and outcomes. Four equally-spaced knots were set at percentiles 5, 35, 65 and 95 according to Harrell's recommendation 28 . To account for differences in assay methods, FT4 was converted to multiples of the upper limit of the assay reference range (ULN). Restricted cubic splines were also used to model the longitudinal FT4 change in in the first 24-months of treatment with cubic knots set at 0, 3, 6, 9, 12, and 18 months.
Serial thyroid function tests were missing in 29% of patients. The characteristics of patients with thyroid tests were comparable to those with missing tests except that patients with tests were younger (mean age 47 vs 49 years, P<0.001), and missing tests were more frequent in patients treated with antithyroid drugs compared to radioiodine or surgery (37% vs 3% vs 16%, P<0.001) (supplementary appendix, supplementary table 3). Thus, we addressed missing tests in the one-year TSH analysis using multiple variable imputation by chained equations 29 under the missing at random assumption (supplementary appendix). We generated 50 imputed datasets with 500 iterations and fitted Cox proportional models within each dataset after which estimates were pooled according to Rubin's rules. Sensitivity analysis using a complete case analysis gave similar results, so we report results from the imputed datasets while the complete case analysis is presented in the supplementary appendix. Statistical analysis was performed via remote desktop with the SAIL Databank using Stata version 16 for Windows (Stata Corp., College Station, TXS, USA).
Regulatory Approvals
The study was registered with the Research and Development Office of Cwm Taf Health Board and approval for data linkage with individual health boards was obtained (reference CT/688/140049/16). Approval for access to anonymised data in the SAIL databank was granted by the SAIL Information Governance Review panel (project reference, 0233). Ethical permission is granted for conducting data analysis in the SAIL Databank and separate ethics committee review was not required for this study.
Role of the funding source
The funding source had no role in study design, data analysis, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The relationship between FT4 and outcomes was modelled with restricted cubic splines which showed increasing hazard with FT4 concentrations above the reference range (figure 5). This relationship was seen in the whole cohort and in drug-treated patients but not radioiodine-treated patients ( figure 5 ). Cubic splines were also used to model the longitudinal change in FT4 after diagnosis. All treatment groups showed a rapid drop in FT4 after diagnosis which was most pronounced and sustained in the successfully treated radioiodine group (supplementary figure 2).
RESULTS
DISCUSSION
We have used linked health records to evaluate all-cause mortality and cardiovascular event risk in patients with Graves' disease and compared outcomes according to the modality and effectiveness of primary treatment. Compared to population controls, Graves' disease patients had a 23% increase in all-cause mortality and over twice the risk of a major cardiovascular event. Furthermore, early and successful treatment with radioiodine was associated with a 50% reduction in mortality compared to primary treatment with antithyroid drugs. Notably, survival advantages were not seen in radioiodine treated patients who failed to achieve control of hyperthyroidism. Patients with persistently low-TSH after one-year of treatment had a 55% increase in mortality even in patients treated with antithyroid drugs alone. Thus, for the first time, we show that mortality in patients with Graves' disease is reduced by early and intensive correction of hyperthyroidism regardless of therapy modality.
Our findings confirm the increased mortality risk previously reported in some 19, 20, 22 but not all 17, 30 hyperthyroidism outcome studies. However, only a few studies to date have specifically addressed mortality risk in relation to hyperthyroidism treatment.
Previous large-scale cohort-studies suggested an excess of cardiovascular mortality in radioiodine-treated patients compared to the background population 15, 17, 18, 31 In the present study, we have employed a study design that distinguished treatment effects from the effects of hyperthyroidism to show that the predictor of cardiovascular morbidity and mortality is the effectiveness of primary treatment rather than therapy modality per se. Our one-year TSH analysis shows that the excess mortality in Graves' disease is driven by exposure to uncontrolled hyperthyroidism and that elimination of the hyperthyroid state whether with antithyroid drugs or radioiodine yields survival benefits. This is biologically plausible
given the established association of hyperthyroidism with cardiovascular disease 4 and is consistent with a recent Danish register-based study that reported excess mortality in association with cumulative periods of low-TSH in patients with treated and untreated hyperthyroidism 14 . Subsequent analyses of the Danish register also showed increased mortality with cumulative hypothyroidism exposure 33 highlighting the need for strict surveillance of therapy to avoid periods of uncontrolled hypothyroidism or hyperthyroidism. As our data shows, persistent thyroid dysfunction is common during Graves' disease therapy, with low or high TSH recorded in 58% of patients at one-year.
The choice of primary therapy in Graves' disease is currently driven by regional Ours is the first large-scale hyperthyroidism cohort study to exploit TRAbs as a specific Graves' disease marker, thereby excluding patients with toxic nodules, thyroiditis, or non-thyroidal illness. By employing a landmark regression approach, we eliminated treatment time bias and additionally provided a clinically relevant timepoint from which to evaluate primary therapy. Our study limitation is that the retrospective design could have introduced bias from undocumented confounders such as smoking, orbitopathy, physician treatment preference, patient compliance with thionamides, and unrecorded exposure to thyroid hormone excess. However, our adjustments for comorbidity and biochemical characteristics would to some extent have adjusted for these confounders. In keeping with conventional practice, patients with more severe baseline disease received radioiodine, but it is unlikely that this influenced our results given that both radioiodine-treated groups had similar baseline features yet strikingly divergent outcomes. Lastly, thyroid tests were missing in a proportion of patients. However, we minimised potential bias from this using principled imputation methods and robust sensitivity checks. Ultimately, potential confounders will only be fully addressed in well-designed, randomised controlled trials which are yet to be undertaken.
In conclusion, early and intensive control of hyperthyroidism in Graves' disease is associated with improvements in long-term cardiovascular morbidity and mortality regardless of therapy modality. Greater emphasis should now be placed on ensuring prompt elimination of hyperthyroidism and maintenance of a normal thyroid status in the management of Graves' disease.
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Supplementary Methods
Modified Charlson Comorbidity Scores
Comorbidity scores were derived using a modification of the Charlson Comorbidity Index (CCI) 1 . Individual scores were calculated as the sum of weighted scores for each of 17 disease conditions identified from hospital admission data using ICD-10 codes for secondary diagnosis fields (DIAG2-DIAG14) 2,3 (supplementary table 1).
Laboratory assays
Between To account for differences in assay methods, FT4 was transformed to multiples of the upper limit of the assay reference range (ULN) and
TSH was categorised as low, normal or high-TSH according to the assay reference range.
Restricted Cubic Spline Regression
We modelled a potential non-linear relationship between the FT4 concentration at 
Missing data imputation
Serial thyroid function tests were available for patients with Graves' disease but not for the control population. Thyroid function tests were missing in 29% of patients.
One In the one-year TSH analysis we addressed missing tests using multiple variable imputation by chained equations 9 . The imputation model comprised all predictor and outcome variables in the analysis. We generated 50 imputed datasets and fitted Cox proportional models within each dataset after which estimates were pooled according to Rubin's rules 10 . In sensitivity analysis we repeated the analysis using a complete case analysis which showed identical estimates to the imputation model ( Supplementary figure 1) . To exclude the possibility that missingness at one-year was associated with stable or worse disease control, we modelled two sensitivity scenarios in which a normal-TSH and a low-TSH at one-year were assumed for patients with serial TSH but missing one-year TSH. These scenarios gave similar results to the imputation model (data not shown). TRAb, TSH receptor antibody; ATD, Antithyroid Drugs; RAI, radioactive iodine; RAI-Group-A, radioiodine with hyperthyroidism control by one-year, and RAI-Group-B, radioiodine without hyperthyroidism control by one-year; *Numbers add up to 171 for 170 patients because one patient had thyroidectomy and died in the first year.
SUPPLEMENTARY FIGURE 1: Hazard ratios for mortality or MACE by one-year TSH, complete case analysis
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Analysis was conducted in all patients and in treatment subgroups according to treatment in the first-year with antithyroid drugs (ATD) or radioactive iodine (RAI). P-int, P values for interaction with treatment group. Results are obtained from a complete case analysis
SUPPLEMENTARY FIGURE 2: FT4 profile post-diagnosis
Longitudinal profile of FT4 concentrations after diagnosis according to treatment groups. FT4 is in multiples of the upper limit of the reference range (X ULN); ATD, antithyroid drugs, RAI-Grp-A, radioiodine with control of hyperthyroidism by 12 months, RAI-Grp-B, radioiodine without control of hyperthyroidism by 12 months 2.0 ATD RAI-Grp-B RAI-Grp-A 
Supplementary Table 6: Mortality and MACE by primary treatment: excluding patients with borderline TRAbs
Patients with borderline TRAbs (1.0-1.5 IU/L) were excluded. HR (95% CI) are obtained from multivariable Cox proportional hazard regression models.
Analysis was conducted in all patients and in subgroups according to treatment in the first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine treatment with control of hyperthyroidism, RAI-Group-B, radioiodine treatment without control of hyperthyroidism 
